Product Development within the National Institutes of Health Radiation and Nuclear Countermeasures Program

被引:0
|
作者
Cassatt, David R. [1 ]
DiCarlo, Andrea L. [1 ]
Molinar-Inglis, Olivia [1 ]
机构
[1] Natl Inst Allergy & Infect Dis NIAID, Radiat & Nucl Countermeasures Program RNCP, Div Allergy Immunol & Transplantat DAIT, Natl Inst Hlth NIH, Rockville, MD USA
关键词
NONHUMAN PRIMATE MODEL; MEDICAL COUNTERMEASURES; IMPROVES SURVIVAL; BODY IRRADIATION; H-ARS; MORTALITY; FILGRASTIM; STOCKPILE; EXPOSURE; INJURY;
D O I
10.1667/RADE-23-00144.1
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Radiation and Nuclear Countermeasures Program (RNCP) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) was established to facilitate the development of medical countermeasures (MCMs) and diagnostic approaches for use in a radiation public health emergency. Approvals for MCMs can be very challenging but are made possible under the United States Food and Drug Administration (FDA) Animal Rule, which is designed to enable licensure of drugs or biologics when clinical efficacy studies are unethical or unfeasible. The NIAID portfolio includes grants, contracts, and inter-agency agreements designed to span all aspects of drug development and encompasses basic research through FDA approval. In addition, NIAID manages an active portfolio of biodosimetry approaches to assess injuries and absorbed radiation levels to guide triage and treatment decisions. NIAID, together with grantees, contractors, and other stakeholders with promising products, works to advance candidate MCMs and biodosimetry tools through an established product development pipeline. In addition to managing grants and contracts, NIAID tests promising candidates in our established preclinical animal models, and the NIAID Program Officers work closely with sponsors as product managers to guide them through the process. In addition, a valuable benefit for stakeholders is working with the NIAID Office of Regulatory Affairs, where NIAID coordinates with the FDA to facilitate interactions between sponsors and the agency. Activities funded by NIAID include basic research (e.g., library screens to discover new products, determine early efficacy, and delineate mechanism of action) and the development of small and large animal models of radiation-induced hematopoietic, gastrointestinal, lung, kidney, and skin injury, radiation combined injury, and radionuclide decorporation. NIAID also sponsors Good Laboratory Practice product safety, pharmacokinetic, pharmacodynamic, and toxicology studies, as well as efficacy and dose-ranging studies to optimize product regimens. For later-stage candidates, NIAID funds large-scale manufacturing and formulation development of products. The program also supports Phase 1 human clinical studies to ensure human safety and to bridge pharmacokinetic, pharmacodynamic, and efficacy data from animals to humans. To date, NIAID has supported >900 animal studies and one clinical study, evaluating >500 new/repurposed radiation MCMs and biodosimetric approaches. NIAID sponsorship led to the approval of three of the six drugs for acute radiation syndrome under the FDA Animal Rule, five Investigational New Drug applications, and 18 additional submissions for Investigational Device Exemptions, while advancing 38 projects to the Biomedical Advanced Research and Development Authority for follow-on research and development. (c) 2024 by Radiation Research Society
引用
收藏
页码:471 / 478
页数:8
相关论文
共 50 条
  • [41] Future directions of the National Institutes of Health Science of Behavior Change Program
    Keller, Chandra
    Ferrer, Rebecca A.
    King, Rosalind B.
    Collier, Elaine
    TRANSLATIONAL BEHAVIORAL MEDICINE, 2021, 11 (09) : 1795 - 1801
  • [42] THE NATIONAL-INSTITUTES-OF-HEALTH ANIMAL HANDLERS MEDICAL SURVEILLANCE PROGRAM
    RIVERA, JC
    BAYER, RA
    JOHNSON, DK
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 1984, 26 (02) : 115 - 117
  • [43] Community Engagement Alliance (CEAL): A National Institutes of Health Program to Advance Health Equity
    Mensah, George A.
    Johnson, Lenora E.
    Zhang, Xinzhi
    Stinson, Nathan, Jr.
    Carrington, Kelli
    Malla, Gargya
    Land, Stephanie R.
    Huff, Erynn
    Freeman, Naomi
    Stoney, Catherine
    Ampey, Bryan
    Paltoo, Dina
    Clark, Dave
    Rajapakse, Nishadi
    Ilias, Maliha R.
    Haase, Karen Plevock
    Punturieri, Antonello
    Kurilla, Michael G.
    Archer, Hillary
    Bolek, Michelle
    Santos, Melanie
    Wilson-Frederick, Shondelle
    Devaney, Stephanie
    Marshall, Vanessa
    Farhat, Tilda
    Hooper, Monica Webb
    Wilson, David R.
    Perez-Stable, Eliseo J.
    Gibbons, Gary H.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2024, 114 : S12 - S17
  • [44] Highlighting the NIAID Radiation and Nuclear Countermeasures Program's Commitment to Training and Diversifying the Radiation Workforce
    Molinar-Inglis, Olivia
    Price, LeShawndra N.
    DiCarlo, Andrea L.
    RADIATION RESEARCH, 2024, 201 (04) : 330 - 337
  • [45] Chronic conditions in women: the development of a National Institutes of health framework
    Temkin, Sarah M. M.
    Barr, Elizabeth
    Moore, Holly
    Caviston, Juliane P. P.
    Regensteiner, Judith G. G.
    Clayton, Janine A. A.
    BMC WOMENS HEALTH, 2023, 23 (01)
  • [46] Chronic conditions in women: the development of a National Institutes of health framework
    Sarah M. Temkin
    Elizabeth Barr
    Holly Moore
    Juliane P. Caviston
    Judith G. Regensteiner
    Janine A. Clayton
    BMC Women's Health, 23
  • [47] National Nuclear Forensics Expertise Development Program
    Kentis, Samantha E.
    Ulicny, William D.
    CURRENT STATUS, TRENDS, AND NEEDS IN RADIOCHEMICAL EDUCATION: THE US AND ABROAD, 2009, 1164 : 47 - 51
  • [48] National nuclear forensics expertise development program
    Kentis, Samantha E.
    Ulicny, William D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [49] Interest in metabolomics continues to grow within US National Institutes of Health (NIH)
    Rima Kaddurah-Daouk
    Metabolomics, 2012, 8 : 754 - 755